X hits on this document

427 views

0 shares

0 downloads

0 comments

41 / 170

8

this period, supporting a beneficial effect at the level of the alpha cell. In addition to

9

decreasing plasma glucose following oral glucose challenge, treatment with Saxagliptin

10

led to statistically significant reductions in fasting plasma glucose versus control in all

11

phase 3 studies. In the six pivotal studies, Saxagliptin 5 mgs led to decreases in fasting

12

plasma glucose ranging from 10mgs to 23 mg/dL relative to control. In these studies,

13

differences in fasting plasma glucose between Saxagliptin and control were seen as early

14

as week two, the earliest time point of measurement. The impact of Saxagliptin on

15

fasting plasma glucose provided clinical evidence for improvement in basal beta cell

16

function as also indicated by corresponding increases in phase 2b.

4

mgs led to decreases of 31 mgs to 50 mg/dL relative to control in two-hour plasma

5

glucose. The reductions in postprandial glucose we saw in conjunction with increases in

6

Insulin provide evidence for the effect of Saxagliptin in improving beta cell function.

18

antihyperglycemic effects across subgroups of demographic and baseline diabetes

19

characteristics. This figure summarizes control subtracted A1c lowering from baseline

20

by gender, race, age, A1c at baseline, duration of diabetes, and creatinine clearance for

21

Saxagliptin 5 mgs as add-on therapy to Metformin. Consistent and clinically meaningful

22

reductions in A1c that is between 0.6% and 1% were seen for all sub groups.

7

In addition, we also observed decreases in postprandial glucagon during

40

17

Treatment with Saxagliptin consistently led to beneficial

1

significant decreases in glucose at 120 minutes as well as three-hour glucose area

2

under the curve following standard oral glucose challenge versus control.

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

3

As shown in this figure, in the six pivotal phase 3 studies, Saxagliptin 5

23

24

In summary, Saxagliptin 5 mgs given as monotherapy, add-on

combination treatment, and initial combination therapy with Metformin led to consistent,

Document info
Document views427
Page views427
Page last viewedSun Dec 04 01:38:34 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments